Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.52 |
| ▸ | VNN1 | O95497 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.44 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.43 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.43 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5175426 | 0.85 | LMNA (0.78) | LMNADGAT2EPHX2NR1H4ERCC1 | |
| SCHEMBL3272257 | 0.85 | EPHX2 (0.60) | DGAT2VNN1EPHX2NR1H4MAPK14 | |
| SCHEMBL5178683 | 0.81 | CNR1 (0.48) | VNN1CNR1MAPK14 | |
| SCHEMBL5175538 | 0.79 | ERCC1 (0.54) | LMNAVNN1EPHX2NR1H4ERCC1 | |
| SCHEMBL5188541 | 0.78 | P2RX7 (0.53) | LMNAEPHX2NR1H4ERCC1ERCC4 | |
| SCHEMBL3581264 | 0.76 | HTR2C (0.53) | DGAT2VNN1EPHX2NR1H4MAPK14 | |
| SCHEMBL3584100 | 0.76 | MAPK14 (0.53) | DGAT2EPHX2NR1H4MAPK14FFAR2 | |
| SCHEMBL5177646 | 0.76 | MAPK14 (0.53) | DGAT2VNN1EPHX2NR1H4MAPK14 | |
| SCHEMBL5633995 | 0.76 | TRPV1 (0.57) | VNN1CNR1MAPK14 | |
| SCHEMBL3272978 | 0.74 | NR1H4 (0.48) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259183-B2 | Indole, indazole and indoline derivatives as CETP inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1776338-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2006013048-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | CETP, NAT1, MTTP | LMNA 697/4885DGAT2 1375/4885VNN1 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.